Does sermorelin raise cancer risk? What long-term research shows so far

People considering sermorelin often ask whether it could raise cancer risk. The honest answer is that long-term data are limited. No study has shown that sermorelin causes cancer, but no long-term study has been designed to rule it out either. This article explains why the question comes up, what the evidence does and does not cover, and who should not use sermorelin.

It is educational content, not medical advice.

How sermorelin works within the body's feedback loop

Sermorelin is a GHRH analog. It signals the pituitary to release the body's own growth hormone, and that release remains subject to normal feedback controls [1]. Growth hormone then raises IGF-1, a growth factor made mainly in the liver.

This differs from injecting growth hormone itself (somatropin), which bypasses the pituitary. That difference in mechanism is real. It is not the same as evidence of a different long-term safety profile, which has not been studied head to head.

Compounded sermorelin is not FDA-approved, and the FDA does not evaluate compounded drugs for safety, effectiveness, or quality.

Why cancer comes up: Growth hormone, IGF-1, and cell growth

IGF-1 promotes cell growth and survival. That is part of normal biology, but it has also led researchers to ask whether higher IGF-1 levels are linked to cancer.

A 2004 systematic review and meta-analysis in The Lancet pooled observational studies on this question. It found that higher circulating IGF-1 was associated with a modestly increased risk of prostate cancer and premenopausal breast cancer [2]. These were associations, not proof that raising IGF-1 causes cancer, and none of the studies involved sermorelin.

Partly because of these concerns, approved growth hormone (somatropin) products list active malignancy as a contraindication and warn about tumor risk [3]. Sermorelin works upstream of growth hormone, but because it raises growth hormone and IGF-1, the same questions are reasonable to ask.

What sermorelin studies and the Geref label say

Most formal safety data for sermorelin come from the clinical program behind Geref, the approved product that was discontinued in 2008. That program focused mainly on children with growth hormone deficiency [4]. In those trials, three of 350 patients stopped because of injection reactions [4].

Those trials were not designed to detect cancer over many years, and they did not follow adults using sermorelin for extended periods. Our article on sermorelin side effects covers the more commonly reported effects.

What long-term data exists and what is missing

What exists:

• Short-term studies, mostly small, showing sermorelin can raise growth hormone and IGF-1 levels in adults [1]
• Safety data from the pediatric Geref program [4]

What is missing:

• Long-term studies in adults that track cancer outcomes
• Studies large enough to detect uncommon risks
• Data on compounded sermorelin specifically
• Head-to-head comparisons of long-term safety between sermorelin and growth hormone

Until such data exist, no one can say that sermorelin is safe over the long term, or that it raises risk. The uncertainty itself is the main finding.

Other long-term questions: Blood pressure, glucose, thyroid

• Glucose. Growth hormone can reduce insulin sensitivity, and somatropin labels warn about glucose intolerance and new or worsening diabetes [3]. Whether this applies to sermorelin over the long term has not been well studied. If you have diabetes or prediabetes, tell your provider.
• Blood pressure. We did not find long-term sermorelin studies that measured blood pressure as an outcome. If you have high blood pressure, include it in your history.
• Thyroid. We did not find long-term sermorelin data on thyroid outcomes. Mention any thyroid condition or medication to your provider.

Who should not use sermorelin

Based on the sermorelin labels and related growth hormone products, sermorelin may not be appropriate for people who:

• Have active cancer or a history of cancer. Growth hormone labels list active malignancy as a contraindication [3]. This is a discussion to have with your provider and, where relevant, your oncologist.
• Are pregnant or breastfeeding. A European label for sermorelin stated it should not be used during pregnancy or breastfeeding [5].
• Have had a hypersensitivity reaction to sermorelin or its ingredients [5].
• Have pituitary or hypothalamic disease, since sermorelin depends on pituitary function.

Like any prescription medication, sermorelin carries risks and possible side effects your provider will review with you.

Questions to ask a provider

• Given my personal and family history of cancer, is sermorelin reasonable for me?
• What is known, and not known, about long-term use?
• Do I need any screening before starting, and who arranges it?
• How will we decide whether to continue, and when to stop?

Luvo does not run labs or provide monitoring. Any screening or testing is arranged through your own provider or physician. For background on the program, see what longevity medicine is.

Common questions

Does sermorelin cause cancer?

There is no evidence showing that sermorelin causes cancer. However, long-term data are limited, and active malignancy is a contraindication for approved growth hormone products [3]. That is why a cancer history matters before starting.

Is sermorelin safer than HGH?

No direct long-term safety comparison exists. Sermorelin works differently, by prompting the pituitary rather than replacing growth hormone [1], but a different mechanism is not proof of lower risk.

What are the most common long-term side effects?

Long-term side effects have not been well characterized. In Geref trials, injection reactions led three of 350 patients to stop [4]. Our sermorelin side effects article has more detail.

Should I get screened before starting?

That is a decision for you and your provider. Any screening would be arranged through your own provider or physician, not through Luvo. Keeping age-appropriate cancer screening up to date is worthwhile either way.

Next steps

If you are weighing whether sermorelin makes sense for you, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review.

Explore Luvo's Longevity Program.